KRYS Stock Risk & Deep Value Analysis
Krystal Biotech Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About KRYS Stock
We analyzed Krystal Biotech Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran KRYS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
KRYS Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is a failure in the pivotal AATD clinical program or significant delays in its regulatory pathway. Given the AATD market is significantly larger than DEB, any setback here could severely impact the company's long-term growth trajectory and valuation, potentially causing a 30-50% stock price decline.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Any unexpected slowdown in Vyjuvek revenue growth or patient starts.
- ⚠
Significant dilution from future capital raises without proportional pipeline advancement.
- ⚠
Adverse events or safety concerns arising from ongoing clinical trials.
Upcoming Risk Events
- 📅
Negative or inconclusive AATD clinical trial results
- 📅
Slower-than-expected Vyjuvek commercial ramp or competitor entry
- 📅
Regulatory hurdles or unexpected safety concerns for pipeline candidates
When to Reconsider
- 🚪
Exit if AATD pivotal trial results are negative or show significant safety issues.
- 🚪
Sell if Vyjuvek quarterly revenue growth decelerates to single digits year-over-year.
- 🚪
Exit if the company announces a substantial capital raise with >15% dilution and no clear near-term catalysts.
Unlock KRYS Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Krystal Biotech Inc (KRYS) Do?
Sector
Healthcare
Industry
Biotechnology
Employees
275
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Visit Krystal Biotech Inc WebsiteInvestment Thesis
Krystal Biotech is a high-growth gene therapy company leveraging its proprietary STAR-D platform and successful Vyjuvek commercialization to expand into larger, underserved rare disease markets like AATD. Strong execution, a validated platform, and significant pipeline catalysts position it for multi-faceted growth and potential market leadership in genetic medicines.
Is KRYS Stock Undervalued?
Unlock the full AI analysis for KRYS
Get the complete DVR score, risk analysis, and more
KRYS Price Targets & Strategy
12-Month Target
$350.00
Bull Case
$420.00
Bear Case
$210.00
Valuation Basis
Based on 12x projected FY2027 revenue of $290M from Vyjuvek and initial AATD pipeline valuation, plus platform value.
Entry Strategy
Consider dollar-cost averaging on dips towards the $220-$230 support zone or the rising 50-day SMA ($235).
Exit Strategy
Take partial profits at $350-$370; consider re-evaluating long-term thesis at $400+. Set stop-loss below key support at $215.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does KRYS Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is durable due to patented gene therapy vectors (STAR-D platform), an established regulatory precedent with Vyjuvek, and proprietary manufacturing. These factors create significant barriers to entry for competitors in their target indications.
Moat Erosion Risks
- •Emergence of superior gene therapy or non-gene therapy treatments from competitors.
- •Patent expirations or successful patent challenges against core technologies.
- •Regulatory changes that favor new entrants or alternative treatment modalities.
KRYS Competitive Moat Analysis
Sign up to see competitive advantages
KRYS Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, fueled by Vyjuvek's initial success and anticipation for the AATD program.
Institutional Sentiment
Positive, with recent analyst target price increases and increased institutional ownership observed in Q4 2025 filings, reflecting confidence in pipeline execution.
Insider Activity (Form 4)
Normal activity observed in Q1 2026, with some executive stock option exercises and subsequent sales for tax purposes, balanced by continued long-term holdings; no significant red-flag insider selling.
Options Flow
Normal options activity, with a balanced put/call ratio, indicating no extreme bearish or bullish institutional positioning.
Earnings Intelligence
Next Earnings
Estimated early May 2026 (Q1 2026)
Surprise Probability
Medium
Historical Earnings Pattern
Typically experiences volatility (±5-10%) around earnings, with positive reactions on Vyjuvek sales beats and strong pipeline updates, and negative reactions on R&D misses or guidance shortfalls.
Key Metrics to Watch
Competitive Position
Top Competitor
Sarepta Therapeutics (SRPT)
Market Share Trend
Gaining market share in the DEB segment due to Vyjuvek's first-in-class status and strong efficacy; poised to gain significant share in AATD if approved.
Valuation vs Peers
Trading at a premium to some gene therapy peers on a near-term revenue multiple, but at a discount when considering the multi-billion dollar TAM of its pipeline if successful.
Competitive Advantages
- •Proprietary STAR-D gene delivery platform with broad applicability
- •Internal manufacturing capabilities for gene therapies, ensuring supply chain control and cost efficiency
- •First-mover advantage in DEB with Vyjuvek, establishing commercial infrastructure and regulatory expertise
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive KRYS Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early May 2026)
- •Continued Vyjuvek commercial uptake and physician adoption updates
- •Phase 3 'TRANSPARENT' trial updates for AATD (Alpha-1 Antitrypsin Deficiency)
Medium-Term (6-18 months)
- •Pivotal clinical data readout for AATD program (2027)
- •Potential regulatory filing for AATD (2027-2028)
- •Advancement of additional pipeline candidates (e.g., CF, rare dermatological conditions)
Long-Term (18+ months)
- •AATD market penetration and expansion beyond DEB
- •STAR-D platform validation for multiple indications, establishing a broad gene therapy franchise
- •Strategic partnerships leveraging proprietary delivery platform for larger indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for KRYS?
- ✓
Acceleration in AATD trial enrollment or positive interim data readouts.
- ✓
Expansion of Vyjuvek into new geographies or age groups.
- ✓
Partnership announcements for pipeline assets beyond core indications.
Bull Case Analysis
See what could go right with Premium
Competing with KRYS
See how Krystal Biotech Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Krystal Biotech Inc KRYS | — | 9.0 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $161.1B | 0.2 | 20.2 | $17.6B | 12.4% | -1.7% | Compare → |
UnitedHealth Group Inc UNH | $300.6B | 0.5 | 17.3 | — | — | — | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Krystal Biotech Inc (KRYS)?
As of March 30, 2026, Krystal Biotech Inc has a DVR Score of 9.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What ticker symbol does Krystal Biotech Inc use?
KRYS is the ticker symbol for Krystal Biotech Inc. The company trades on the NMS.
What is the risk level for KRYS stock?
Our analysis rates Krystal Biotech Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the KRYS DVR analysis updated?
Our AI-powered analysis of Krystal Biotech Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for KRYS (Krystal Biotech Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.